Robert Iseman provided a list of the top 15 considerations for healthcare organizations in choosing outside counsel, for the March 2020 issue of Healthcare Risk Management.

To read the article, which is entitled “Top Factors to Consider in Choosing Outside Counsel,” click here.

Eric Fader was interviewed for the Part B News article, “Attesting to a patient or candidate’s health? Sure, but don’t fudge the truth.”

Click here to read the full article.

On Thursday, May 7, 2020, Benjamin Malerba and Jeff Kaiser will participate in a panel discussion sponsored by the Long Island Chapter of the Association of Certified Fraud Examiners.

The program, to be held at the Westbury Manor, will feature a panel of experts discussing the detection and prosecution of healthcare fraud.

For details and

Eric Fader was quoted in an article, “Court throws out fee policies for medical record sharing; watch for new rules,” in Part B News. The article discussed the recent court decision in Ciox Health, LLC v. Alez Azar, et al., which led to the Department of Health and Human Services modifying its guidance regarding patients’

Marc Ullman will be presenting at the Dietary Supplement Good Manufacturing Practices (GMP) Compliance Seminar on April 16-17, 2020 at the Hilton Garden Inn Melville in Plainview, New York.

EAS Consulting Group will be conducting the seminar to help firms prepare for

Marc Ullman was interviewed for an article in Natural Products Insider entitled “Supplement contract manufacturing recall ‘unprecedented.'”

The article discusses how ABH, along with 859 of its nutritional products brands, was shut down by a U.S. Department of Justice consent decree.

To read the article, click here.

On Thursday, January 30, 2020, Steven Shapiro will present to the New York State Bar Association’s Food, Drug and Cosmetic Law Section as part of its Off-Label Promotion Update. His presentation is entitled “Promotion of CBD following Epidiolex for Rx, OTC drugs and other products.

For information and to register, click here.

On January 29, 2020, Marc Ullman’s opinion piece, “FDA’s lack of CBD guidance is a disservice to Long Island firms,” appeared in Long Island Business News.

Marc notes that an exploding market for CBD products has created a conundrum for companies wishing to cash in. Either they obey FDA’s regulations and lose out, or they break

Marc Ullman spoke with Nutraingredients-USA about a recall of 1,200 products manufactured by Edgewood, NY-based ABH Nature’s Products, Inc. (also doing business as ABH Pharma, Inc. and Stocknutra.com, Inc.). The company issued a recall under a consent decree with the United States District Court for the Eastern District of New York.

The recall is intended to

Marc Ullman spoke to Nutraingredients-USA about a new bill that would include CBD in the definition of dietary supplements in the federal Food, Drug and Cosmetic Act. The legislation is an attempt to cope with the raft of products now on the market that are technically illegal.

Marc said he thinks the bill will only